Kennedy Capital Management LLC increased its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 10.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 666,095 shares of the company's stock after purchasing an additional 61,238 shares during the quarter. Kennedy Capital Management LLC owned 0.45% of Xeris Biopharma worth $2,258,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of the company. Legato Capital Management LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter worth $482,000. Barclays PLC raised its stake in shares of Xeris Biopharma by 87.8% during the 3rd quarter. Barclays PLC now owns 324,472 shares of the company's stock valued at $925,000 after buying an additional 151,685 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Xeris Biopharma by 2.9% in the 3rd quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company's stock valued at $9,502,000 after buying an additional 93,091 shares during the period. Principal Financial Group Inc. boosted its stake in shares of Xeris Biopharma by 30.3% in the third quarter. Principal Financial Group Inc. now owns 102,469 shares of the company's stock worth $292,000 after buying an additional 23,843 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its position in Xeris Biopharma by 106.2% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company's stock valued at $581,000 after acquiring an additional 88,224 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.
Xeris Biopharma Stock Performance
Shares of Xeris Biopharma stock traded up $0.03 during trading hours on Friday, reaching $4.11. 1,906,347 shares of the company were exchanged, compared to its average volume of 1,862,867. The firm has a market cap of $632.69 million, a PE ratio of -9.13 and a beta of 1.37. The stock's fifty day moving average is $4.44 and its 200 day moving average is $3.69. Xeris Biopharma Holdings, Inc. has a 1 year low of $1.69 and a 1 year high of $6.07.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on XERS shares. Jefferies Financial Group reaffirmed a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Piper Sandler restated a "neutral" rating and set a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Leerink Partners raised their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. Finally, Craig Hallum upped their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research note on Friday, March 7th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and a consensus price target of $6.10.
Read Our Latest Analysis on XERS
Insiders Place Their Bets
In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. The trade was a 2.87 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.56% of the stock is owned by company insiders.
About Xeris Biopharma
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
See Also
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
